1 results match your criteria: "Lausanne University Hospital and Agora Translational Cancer Research Center[Affiliation]"
Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma.
Cancers (Basel)
December 2022
Department of Oncology, Lausanne University Hospital and Agora Translational Cancer Research Center, Rue du Bugnon, 1011 Lausanne, Switzerland.
Article Synopsis
- Combined treatment with ipilimumab and nivolumab greatly improves survival for metastatic melanoma patients but also incurs significant healthcare costs, particularly for treatment-related adverse events (irAEs).
- In a study of 62 melanoma patients from 2016 to 2019, 87% experienced at least one irAE, with 50% facing severe irAEs, yet these accounted for only 3% of total treatment expenses.
- Costs were predominantly driven by medication (44%) and hospitalization (39%) related to the disease, while patients who achieved complete responses had lower weekly costs compared to those with progressive disease, suggesting a complex relationship between treatment toxicity and financial impact.